Drug intelligence / Profile preview

MF-018

Development stage: Unknown
Lead developer: Mediforum
Modality: Small Molecules
Administration: Oral

Overview

MF-018 is a non-opioid, small-molecule analgesic candidate derived from a cinnamon extract platform, being developed for neuropathic pain, notably chemotherapy-induced peripheral neuropathy. Company communications describe it as a new class of pain relief compounds intended to reduce reliance on opioids; detailed molecular target and mechanism of action have not been disclosed publicly.[5][8][10]

Beyond the preview

Go deeper on MF-018.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MF-018.

Explore the full profile